EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Long‐term health consequences of congenital adrenal hyperplasia

Riccardo Pofi, Xiaochen Ji, Nils P Krone, Jeremy W Tomlinson

Clinical Endocrinology · 2024-10 · 101 (4) · 318-331

DOI: 10.1111/cen.14967 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Endocrinology, online erschienen am 07.09.2023. Verfasst von Riccardo Pofi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK. Hauptthemen laut MEDLINE: Adrenal Hyperplasia, Congenital. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 229 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIHR Oxford Biomedical Research Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Congenital adrenal hyperplasia (CAH) caused by 21‐hydroxylase deficiency accounts for 95% of all CAH cases and is one of the most common inborn metabolic conditions. The introduction of life‐saving glucocorticoid replacement therapy 70 years ago has changed the perception of CAH from a paediatric disorder into a lifelong, chronic condition affecting patients of all age groups. Alongside health problems that can develop during the time of paediatric care, there is an emerging body of evidence suggesting an increased risk of developing co‐morbidities during adult life in patients with CAH. The mechanisms that drive the negative long‐term outcomes associated with CAH are complex and involve supraphysiological replacement therapies (glucocorticoids and mineralocorticoids), excess adrenal androgens both in the intrauterine and postnatal life, elevated steroid precursors and adrenocorticotropic hormone levels. Alongside a review of mortality outcome, we discuss issues that need to be addressed when caring for the CAH patient including female and male fertility, cardio‐metabolic morbidity, bone health and other important long‐term outcomes of CAH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenal Hyperplasia, CongenitalHumansFemaleMaleGlucocorticoidsFertility

Stichwörter der Autor:innen

congenital adrenal hyperplasiaglucocorticoidlong‐termmineralocorticoidoutcome

Substanzen

Glucocorticoids

Autor:innen und Institutionen

  • Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.
  • Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.
  • Endocrinology and Metabolism Department, The Second Affiliated Hospital, Dalian Medical University, Dalian, China.

Förderung

  • NIHR Oxford Biomedical Research Centre

Zitieren

APA

Pofi, R., Ji, X., Krone, N. P., & Tomlinson, J. W. (2024). Long‐term health consequences of congenital adrenal hyperplasia. Clinical Endocrinology, 101(4), 318-331. https://doi.org/10.1111/cen.14967

Vancouver

Pofi R, Ji X, Krone NP, Tomlinson JW. Long‐term health consequences of congenital adrenal hyperplasia. Clinical Endocrinology. 2024;101(4):318-331. doi:10.1111/cen.14967

BibTeX
@article{Pofi2024,
  author = {Pofi, Riccardo and Ji, Xiaochen and Krone, Nils P and Tomlinson, Jeremy W},
  title = {Long‐term health consequences of congenital adrenal hyperplasia},
  journal = {Clinical Endocrinology},
  year = {2024},
  volume = {101},
  number = {4},
  pages = {318--331},
  doi = {10.1111/cen.14967}
}
Kostenlos starten →